Onderneming Liminal BioSciences Inc.
Aandelen
PJ2
CA53272L2021
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 51 | 14-07-08 | |
Director of Finance/CFO | 51 | 02-03-22 | |
Patrick Sartore
PSD | President | 49 | 01-01-06 |
Gary Bridger
CTO | Chief Tech/Sci/R&D Officer | 61 | 01-05-19 |
Director/Board Member | 67 | 14-05-14 | |
Shrinal Inamdar
IRC | Investor Relations Contact | - | - |
Marie Iskra
LAW | General Counsel | 48 | 01-09-19 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gary Bridger
CTO | Chief Tech/Sci/R&D Officer | 61 | 01-05-19 |
Director/Board Member | 67 | 14-05-14 | |
Alek Krstajic
CHM | Chairman | 60 | 01-09-20 |
Neil Klompas
BRD | Director/Board Member | 52 | 01-05-19 |
Eugene Siklos
BRD | Director/Board Member | 60 | 01-09-20 |
Director/Board Member | 63 | 01-05-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 3 249 534 | 1 258 903 ( 38,74 %) | 0 | 38,74 % |
Bedrijfsgegevens
Liminal BioSciences, Inc.
440, boulevard Armand-Frappier Suite 300
H7V 4B4, Laval
+450 781 0115
http://www.liminalbiosciences.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,86 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,66 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |